Bristol-Myers Squibb signs licensing deal with Novo Nordisk


For discovery research programme focused on autoimmune diseases

Bristol-Myers Squibb has reached an agreement with Novo Nordisk for an exclusive global licence to the Denmark-based company's discovery biologics research programme focused on modulating the innate immune system as a therapy for autoimmune diseases.

Financial terms of the agreement have not been disclosed.

Bristol-Myers Squibb said the agreement supports its long-standing commitment to immunoscience, a core therapeutic area.

Sign up for your free email newsletter

The innate immune system is the body’s first line of defence against pathogens and responds to exogenous agents in an antigen non-specific way to stimulate an immediate protective response. Dysregulated innate immunity plays a critical role in the induction and pathogenesis of autoimmune diseases, the company said.